<DOC>
	<DOCNO>NCT02918539</DOCNO>
	<brief_summary>This registry use identify patient etiology diagnose suspected Alzheimer 's disease positive amyloid scan , indicated interest contact Eli Lilly Company ( Lilly ) Alzheimer 's Disease drug research trial .</brief_summary>
	<brief_title>Registry Amyloid Positive Patients Alzheimer 's Disease Drug Research Trials</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<criteria>Male female patient â‰¥ 50 year age time consent ; Patients objectively verify cognitive impairment etiology diagnose suspected Alzheimer 's disease ; Patients willing make available Avid positive amyloid scan , amyloid scan available , willing undergo amyloid scan via Florbetapir F 18 PET Scan Addendum ; Patients willing contact possible participation Lilly drug research trial target Alzheimer 's disease ; Patients give informed consent legally authorize representative ( LAR ) consent enrollment ; Patients partner ( informant ) willing participate source information least weekly contact patient ( contact inperson , via telephone electronic communication ) . The informant must sufficient contact refer physician feel informant provide meaningful information patient . Patients Mini Mental State Examination ( MMSE ) score &lt; 10 ; Patients amyloidnegative PET scan ( either historical scan scan via Florbetapir F 18 PET Scan Addendum ) ; Patients serious unstable medical condition would exclude completion procedure data collection registry , would likely preclude participation drug research trial ; Patients participate clinical trial investigate antiamyloid agent ; Patients currently participate clinical trial investigational agent ; Patients , opinion physician , otherwise unsuitable registry .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>